Navigation Links
Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer

Study Fails to Meet Primary Endpoint of Improvement in Overall Survival

WESTMINSTER, Colo., June 19, 2007 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. today announced top line results from ENRICH, the Company's pivotal Phase 3 study of Efaproxyn (efaproxiral) plus whole brain radiation therapy (WBRT) in women with brain metastases originating from breast cancer. The study failed to achieve its primary endpoint of demonstrating a statistically significant improvement in overall survival in patients receiving Efaproxyn plus WBRT, compared to patients receiving WBRT alone. Based on these results, the Company intends to discontinue the development of Efaproxyn and focus on advancing the development of PDX (pralatrexate), its novel antifolate currently under evaluation in a pivotal Phase 2 study in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

"I would like to acknowledge the patients and investigators for their participation in the ENRICH study," said Paul L. Berns, President and Chief Executive Officer of Allos. "We continue to move forward with focus and determination in advancing the clinical development of PDX and RH1, and look forward to providing future updates on our clinical progress."

Results of the ENRICH study indicated that patients who received EFAPROXYN plus WBRT did not experience a statistically significant improvement in survival compared to patients who received WBRT alone, according to a stratified log rank analysis of overall survival (8.5 months vs. 7.5 months; hazard ratio 0.87, p-value = 0.23). All secondary efficacy endpoints also failed to achieve statistical significance. The study safety results demonstrated that EFAPROXYN was generally well tolerated. The most common Grade 3-4 adverse events that occurred more often in the EFAPROXYN arm included headache, hypoxia and vomiting. Adverse events in the study appeared to be similar to those obser
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:7/23/2008)...Pharmaceuticals (SPI) has filed,an Investigational...l,testing of a proprietary formulation of ebselen ... loss or ototoxicity. The oral capsule,containing ...e lung cancer,and head and neck cancer patients re...e second development program for SPI to enter clin...
(Date:7/23/2008)... Have Greater Concentrations of,Stem Cells, ARLIN.../ -- Fat removed,from the lower abdomen and inner ...lent source of stem cells, with higher stem cell c...s a Brazilian-based study in August,s,Plastic and ...urnal of the,American Society of Plastic Surgeons ...
(Date:7/23/2008)...th Protein Therapeutics that Modulate Al..., Mass., July 23 /- Taligen Therapeut...ate growth plan with the,appointment of Abbie Celn...tablishment of its headquarters in Cambridge, Mass...-founder of the company who remains president., U...
(Date:7/22/2008)...nin Medical, a leading innovator,of physiological ...ntered,the clinical testing phase with its breakth...tion. Today,s most common application for this,tec...al blood oxygenation,in the brain -- cerebral oxim...going clinical study at the,Duke University Medica...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Symmetry Medical Delays 10 K Filing to Complete Review 15357 1Symmetry Medical Delays 10 K Filing to Complete Review 15357 2Symmetry Medical Delays 10 K Filing to Complete Review 15357 3Symmetry Medical Delays 10 K Filing to Complete Review 15357 4Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 1Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 2Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 3Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 1Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 2Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 3Immucor Schedules Third Quarter Earnings Release and Conference Call 15345 1Immucor Schedules Third Quarter Earnings Release and Conference Call 15345 2
...ented at 2007 APA Meeting Also Showed No,Significa...COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstC... - one examining the,effect of desvenlafaxine succ... symptoms associated with major depressive disorde...hat examined the,effect of desvenlafaxine succinat...
...7 Percent Reduction in Risk of Hospitalization,fro...PARK, Ill., May 22, 2007 /PRNewswire-FirstCall/ --...alysis of a pivotal study,presented at the Digesti... showing patients with moderate to severely active...b) maintenance,therapy were almost 60 percent less...
Other Medicine Technology:Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 2Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 3Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 4Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 5Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo 6New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 2New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 3New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 4New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 5New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 6New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 7
(Date:7/25/2008)...Robert J. Reilly, Joins Aethon Team, PITTSBURGH, ...ethon.com ), the leading developer of mobile robot...ounced that Robert J. Reilly has,joined the compan...cer., Reilly, who was most recently Vice Presiden...ecialty Pharmacy Division, brings more than 30,yea...
(Date:7/25/2008)...an cause immune system changes , , FRIDA...linking gastroesophageal reflux disease (GERD) and...ical Center researchers. , An association betwe..., and since then studies have shown that between 5...xperience GERD symptoms. But the actual link betwe...
(Date:7/25/2008)...mation Association (DIA) and the Food and Drug Adm...iative (CPI) on the Move: Complexities and Challen...cal Path Transporter Workshop (October 2-3; North ... PA (PRWEB) July 25, 2005-- The http://www.diahom...he Food and Drug Administration (FDA) will host th...
(Date:7/24/2008)...wswire/ -- Speaker Nancy Pelosi,released the follo...Lantos,and Henry J. Hyde Global Leadership Against...on Act of 2008. The bill, which passed the Senate ... of 303 to 115 and will now go,the President for h...historic vote to pass landmark legislation to,reau...
Breaking Medicine News(10 mins):Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:People With GERD More Likely to Develop Asthma 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3Health News:Pelosi Statement on House Passage of Global AIDS Legislation 2
... over have one more reason to raise a toast- a for...s on how you // can pep-up your spirits and reli...Wine Studies at Coventry University, and author of...worthwhile to recall the laws while popping open a...
...ector, K. Sellamuthu, has ordered distribution of ...g places // such as tea stalls, hair cutting sal... as these are the places where large number of pub...was initiated by the Tamilnadu State AIDS Control ...
... delayed to a great extent by taking walks thrice ...ood flow // and leg pain, according to a recent ... be improved through the exercise. As a part of th... of 417 men and women by measuring the distance th...
...Science organization reveal that the detox tablets...The body // has the capacity to take what is esse...he substances that are ingested are not harmful an...he detox industry that includes everything from di...
Other Medicine News:
... is recommended for separations of DNA fragments <...at are easy to handle, and remains flexible even a...f cracking or breaking. Certified PCR agarose, unl...ilar sieving properties, is a standard gelling tem...
The PK TP System utilizes fixed chicken erythrocytes sensitized with components of the pathogenic T. pallidum (Nichols Strain) to perform a qualitative screening of Treponema pallidum in human serum
Agarose-HR™ High Resolution - Efficiently separates DNA fragments from 50 to 1000 bp. It is useful for sizing PCR fragments, small DNA fragments generated by restriction enzyme digestion, and d
...ning donors on the PK7200 Automated Microplate Sys...d to a gelatin particle for the detection of cytom...f the CMV assay as compared to EIA measures 99.8% ...cle as the carrier provides excellent lot-to-lot c...
Medicine Products: